JP2002512800A5 - - Google Patents

Download PDF

Info

Publication number
JP2002512800A5
JP2002512800A5 JP2000546017A JP2000546017A JP2002512800A5 JP 2002512800 A5 JP2002512800 A5 JP 2002512800A5 JP 2000546017 A JP2000546017 A JP 2000546017A JP 2000546017 A JP2000546017 A JP 2000546017A JP 2002512800 A5 JP2002512800 A5 JP 2002512800A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
polynucleotide
nucleotide sequence
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000546017A
Other languages
English (en)
Japanese (ja)
Other versions
JP4718009B2 (ja
JP2002512800A (ja
Filing date
Publication date
Priority claimed from GBGB9808866.9A external-priority patent/GB9808866D0/en
Application filed filed Critical
Publication of JP2002512800A publication Critical patent/JP2002512800A/ja
Publication of JP2002512800A5 publication Critical patent/JP2002512800A5/ja
Application granted granted Critical
Publication of JP4718009B2 publication Critical patent/JP4718009B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000546017A 1998-04-24 1999-04-20 髄膜炎菌由来のbasb006ポリヌクレオチドおよびポリペプチド Expired - Fee Related JP4718009B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9808866.9A GB9808866D0 (en) 1998-04-24 1998-04-24 Novel compounds
GB9808866.9 1998-04-24
PCT/EP1999/002766 WO1999055873A2 (en) 1998-04-24 1999-04-20 Basb006 polynucleotide(s) and polypeptides from neisseria meningitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010044312A Division JP2010166920A (ja) 1998-04-24 2010-03-01 髄膜炎菌由来のbasb006ポリヌクレオチドおよびポリペプチド

Publications (3)

Publication Number Publication Date
JP2002512800A JP2002512800A (ja) 2002-05-08
JP2002512800A5 true JP2002512800A5 (enExample) 2006-04-27
JP4718009B2 JP4718009B2 (ja) 2011-07-06

Family

ID=10830985

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000546017A Expired - Fee Related JP4718009B2 (ja) 1998-04-24 1999-04-20 髄膜炎菌由来のbasb006ポリヌクレオチドおよびポリペプチド
JP2010044312A Pending JP2010166920A (ja) 1998-04-24 2010-03-01 髄膜炎菌由来のbasb006ポリヌクレオチドおよびポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010044312A Pending JP2010166920A (ja) 1998-04-24 2010-03-01 髄膜炎菌由来のbasb006ポリヌクレオチドおよびポリペプチド

Country Status (8)

Country Link
US (3) US6696062B1 (enExample)
EP (2) EP2360260A1 (enExample)
JP (2) JP4718009B2 (enExample)
CN (1) CN1203180C (enExample)
AU (1) AU3928499A (enExample)
CA (1) CA2326375A1 (enExample)
GB (1) GB9808866D0 (enExample)
WO (1) WO1999055873A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
DE69841807D1 (de) * 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1412381B1 (en) 2001-07-27 2010-06-02 Novartis Vaccines and Diagnostics S.r.l. Antibodies against meningococcal adhesin app
RU2317106C2 (ru) * 2002-08-02 2008-02-20 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
WO2004014417A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis
SI2353608T1 (sl) 2002-10-11 2020-12-31 Glaxosmithkline Biologicals Sa Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
ES2346314T3 (es) 2003-10-02 2010-10-14 Glaxosmithkline Biolog Sa Antigenos de b. pertussis y uso de los mismos en vacunacion.
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
EP2296699A4 (en) 2008-05-30 2013-11-13 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army POLYVALENT MENINGOCOCCULAR FUEL WITH NATIVE OUTER MEMBRANE VESICLES, METHOD OF MANUFACTURE AND USE
WO2011110634A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
BR112012022800A2 (pt) 2010-03-11 2018-05-15 Glaxosmithkline Biologicals Sa composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5747292A (en) 1993-04-06 1998-05-05 Fred Hutchinson Cancer Research Center Chimeric cytokine receptors in lymphocytes
EP0705341A1 (en) 1993-06-07 1996-04-10 Amgen Inc. Hybrid receptor molecules
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6245337B1 (en) * 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
US6121037A (en) * 1994-10-18 2000-09-19 Stojiljkovic; Igor Bacterial hemoglobin receptor genes
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
AU5552396A (en) * 1995-04-21 1996-11-07 Human Genome Sciences, Inc. Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
PT939647E (pt) * 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
DE69841807D1 (de) * 1997-11-06 2010-09-16 Novartis Vaccines & Diagnostic Neisseriale antigene
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9808734D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
ES2337650T3 (es) * 1999-03-12 2010-04-28 Glaxosmithkline Biologicals S.A. Polipeptidos antigenicos de neisseria meningitidis polinucleotidos y anticuerpos protectores correspondientes.
GB0025171D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
EP1412381B1 (en) * 2001-07-27 2010-06-02 Novartis Vaccines and Diagnostics S.r.l. Antibodies against meningococcal adhesin app

Similar Documents

Publication Publication Date Title
JP2002512800A5 (enExample)
JP2693145B2 (ja) 乳頭腫ウイルス型特異的抗体
Svehag et al. THE FORMATION AND PROPERTIES OF POLIOVIRUS-NEUTRALIZING ANTIBODY: II. 19S and 7S Antibody Formation: Differences in Antigen Dose Requirement for Sustained Synthesis, Anamnesis, and Sensitivity to X-Irradiation
JP2010166921A5 (enExample)
KR860700090A (ko) 어드헤신(Adhesin)항원
JPS61289888A (ja) ワクシニアdna
RU99122686A (ru) Модифицированные молекулы фно альфа, днк, кодирующие эти модифицированные молекулы фно альфа, и вакцины, включающие эти модифицированные молекулы фно альфа и днк
CN86102858A (zh) 制备猪支原体的重组表面抗原及其疫苗的方法
JP2006523453A5 (enExample)
JPH09505723A (ja) 43kdヒトガン抗原からの免疫反応性ペプチド配列
BG64627B1 (bg) Нсv геномни последователности за диагностика и лечение
US20090074781A1 (en) Dengue virus peptide vaccine and methods of preparing and using the same
IL139613A (en) Compositions of polynucleotide (s) basb029 and polypeptides of neisseria meningitidis, methods of production and their uses
CA2217522A1 (en) Isolated frpb nucleic acid molecule and vaccine
CN1045603A (zh) 筛选系统
WO2022071513A1 (ja) SARS-CoV-2に対する改良型DNAワクチン
CN113186223A (zh) 一种新冠病毒疫苗的表达载体及其构建方法、应用和疫苗
JP4820489B2 (ja) ヒト型結核菌により発現され且つbcgによって発現されないタンパク質、ならびに診断薬およびワクチンとしてのそれらの使用
CN116970058B (zh) 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
JPH05501401A (ja) 組換え微生物との転移増殖によるワクチン又はトキソイド製剤及び免疫の方法
JP2003533990A (ja) 百日咳菌、パラ百日咳菌および気管支敗血症菌のペルタクチンの繰返し領域の多型性を有するポリペプチド、ならびに診断および免疫原性組成物におけるその使用
JPH08510714A (ja) エプスタイン−バーウィルスからの免疫反応性ペプチド
CN111138553B (zh) 一种融合蛋白及一种弓形虫亚单位疫苗及其疫苗组合物
CN117024522A (zh) 针对pik3ca基因e545k突变的肿瘤新抗原多肽及其应用
DE60025522T2 (de) Mycoplasma mycoides subsp. mycoides sc antigenisches lppq protein, seine herstellung und verwendung